Initial treatment regimen. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Patients baseline characteristics. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Overall survival. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Progression-free survival by treatment. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Maintenance regimen and adverse event management. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

BCC-specific survival. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Phase 1 pre- and post-test Means (<i>M</i>), Standard Deviations (<i>SD</i>), between group effect sizes (<i>d</i>), and RMANOVA results (<i>F</i>-value, <i>p</i>-value) for interv... by Wendy C. Crone (2262169)

Chamber. by Yoichiro Kitajima (4319455)

Subjects:

Respiratory pattern. by Yoichiro Kitajima (4319455)

Subjects:

Protocols. by Yoichiro Kitajima (4319455)

Subjects:

Effect of AGPAT3 downregulation on the mTORC1 signaling pathway. by Hadi Alizadeh (20854757)

Subjects:

Introduction of potential genes and signal pathways related to cisplatin resistance in the A2780 cell line based on Bioinformatics analysis. by Hadi Alizadeh (20854757)

Subjects:

Mechanism of AGPAT3-mediated mTORC1 activation and its downstream effects. by Hadi Alizadeh (20854757)

Subjects:

Effect of AGPAT3 overexpression on mTORC1 signaling pathway. by Hadi Alizadeh (20854757)

Subjects:

Differentially expressed genes in A2780 resistant and sensitive to cisplatin ovarian cancer originated cell lines. by Hadi Alizadeh (20854757)

Subjects:

Cell cycle analysis of A2780 cells following AGPAT3 overexpression. by Hadi Alizadeh (20854757)

Subjects:

Characterization of cisplatin resistance phenotype in A2780 and A2780cp cells. by Hadi Alizadeh (20854757)

Subjects:

Viability and drug resistance of A2780 cells following AGPAT3 overexpression. by Hadi Alizadeh (20854757)

Subjects:

Presenting the original images of Western blotting analysis. by Hadi Alizadeh (20854757)

Subjects:

Mice with a decrease in α7 expression show no behavioral preference to a conditioned odor. by Jennifer L. Hellier (326477)